Jmjd6-flox 基因敲除小鼠

1. Zhou, Jin, Simon, Jeremy M, Liao, Chengheng, Brugarolas, James, Zhang, Qing. 2022. An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. In Molecular cell, 82, 3030-3044.e8. doi:10.1016/j.molcel.2022.06.003. https://pubmed.ncbi.nlm.nih.gov/35764091/

2. Wang, Lei, Wen, Mingyue, Cao, Xuetao. 2019. Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses. In Science (New York, N.Y.), 365, . doi:10.1126/science.aav0758. https://pubmed.ncbi.nlm.nih.gov/31320558/

3. Wong, Matthew, Sun, Yuting, Xi, Zhichao, George, Rani E, Liu, Tao. 2019. JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. In Nature communications, 10, 3319. doi:10.1038/s41467-019-11132-w. https://pubmed.ncbi.nlm.nih.gov/31346162/

4. Kosai-Fujimoto, Yukiko, Itoh, Shinji, Yugawa, Kyohei, Yoshizumi, Tomoharu, Mori, Masaki. 2022. Impact of JMJD6 on intrahepatic cholangiocarcinoma. In Molecular and clinical oncology, 17, 131. doi:10.3892/mco.2022.2564. https://pubmed.ncbi.nlm.nih.gov/35911665/

5. Gao, Wei-Wei, Xiao, Rong-Quan, Zhang, Wen-Juan, Rosenfeld, Michael G, Liu, Wen. 2018. JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex. In Molecular cell, 70, 340-357.e8. doi:10.1016/j.molcel.2018.03.006. https://pubmed.ncbi.nlm.nih.gov/29628309/